Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H221

UPID:
ABCG8_HUMAN

ALTERNATIVE NAMES:
Sterolin-2

ALTERNATIVE UPACC:
Q9H221; Q53QN8

BACKGROUND:
The ATP-binding cassette sub-family G member 8, known as Sterolin-2, alongside ABCG5, orchestrates the selective transport of dietary cholesterol and sterol excretion. This heterodimer's function is essential for maintaining sterol homeostasis, showcasing its critical role in lipid metabolism and cellular health.

THERAPEUTIC SIGNIFICANCE:
ABCG8's association with diseases such as gallbladder disease 4 and sitosterolemia 1, which stem from impaired cholesterol and sterol metabolism, positions it as a key target for drug discovery. Exploring ABCG8's mechanisms offers a promising pathway to developing novel treatments for these lipid-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.